Amneal Pharma Faces Parkinson's Candidate Setback with FDA's CRL
- July 03rd, 2023
- 341 views
Shares of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) dropped over 10% in after-hours trading due to a Complete Response Letter from the FDA regarding the company's New Drug Application for IPX203 to treat Parkinson's disease, a neurological condition characterized by involuntary and uncontrolled movements, including tremors, rigidity, and challenges with balance and coordination.
According to Amneal, the FDA requested additional information on the ingredient carbidopa, and no issues were identified in the letter regarding the efficacy or manufacturing of IPX203.
The company stated that it will work with the FDA to address the comments and move forward, and the financial guidance for 2023 remains unaffected by this development.
$AMRX was trading at $2.65 (-13.11%) in the extended session after the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login